Search results
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
Motley Fool via Yahoo Finance· 4 days agoThe 10 stocks that made the cut could produce monster returns in the coming...including guidance on...
The Newest Side Effect of a Popular Weight Loss Drug
Mercola· 6 days agoRapid weight loss drugs continue to surge in popularity, making them the major contributor to the 13.5% increase in spending on prescription medications ...
6 Things That Can Happen When You Stop Taking Mounjaro, Zepbound
Healthline· 17 hours agoStopping them can prompt weight regain, blood sugar spikes, and increased appetite, among other side...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia...with an easy-to-follow blueprint for success, including guidance on building a portfolio ...
Structure pill leads to competitive weight loss in obesity study
BioPharma Dive via Yahoo Finance· 4 days agoShares in the company soared by more than 50% as study data showed the pill led to similar levels of...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Motley Fool via Yahoo Finance· 6 days agoIf a new weight loss drug comes to market, which proves better than the current options, that could...
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
InvestorPlace· 10 hours agoPharma stocks have two unique characteristics that can make them great investments for many...
Weighty decisions: GLP-1 considerations during benefits renewal season
BenefitsPRO· 13 hours agoRenewal season is here, and employers are reevaluating their health insurance offerings with one...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Motley Fool via Yahoo Finance· 5 days agoEarlier this year, it reported highly encouraging phase 1 results for an oral anti-diabetes...